NICE set to take away standard of care for over 1000 lung cancer patients

The National Institute for Health and Care Excellence (NICE) has recommended that relapsed (second line) non-small cell lung cancer (NSCLC) patients no longer have access to cancer pill Tarceva® (erlotinib) because it does not meet their criteria for clinical and cost-effectiveness.(

Source: Pharmacy Europe - February 13, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Legislation & regulation Oncology Latest News Source Type: news